CUREVAC
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CUREVAC
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Contact:
+49707198830
Total Funding:
1.85 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
2019-06-01
Board_member
Board_member
Board_member
Current Employees Featured
Franz-Werner Haas Chief Corporate Officer @ CureVac
Chief Corporate Officer
2012-01-01
Florian von der Mulbe Co-Founder, CPO @ CureVac
Co-Founder, CPO
2018-01-01
Ulrike Gnad-Vogt Chief Medical Officer @ CureVac
Chief Medical Officer
2013-08-01
Nigel Horscroft Area Head - Molecular Therapy @ CureVac
Area Head - Molecular Therapy
2017-01-01
Mariola Fotin-Mleczek Chief Technology Officer @ CureVac
Chief Technology Officer
2018-10-01
George Siber Member of SAB @ CureVac
Member of SAB
2015-01-01
Patrick Baumhof Vice President Formulation & Delivery @ CureVac
Vice President Formulation & Delivery
2017-01-01
Pierre Kemula CFO @ CureVac
CFO
2016-10-01
Steve Pascolo Co-Founder and CSO @ CureVac
Co-Founder and CSO
2000-05-01
Regina Heidenreich Head of Immunotherapy @ CureVac
Head of Immunotherapy
2012-12-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-08 | Frame Cancer Therapeutics | Frame Cancer Therapeutics acquired by CureVac | 32 M EUR |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CureVac
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - CureVac
GlaxoSmithKline
GlaxoSmithKline investment in Corporate Round - CureVac
European Investment Bank
European Investment Bank investment in Debt Financing - CureVac
KfW
KfW investment in Venture Round - CureVac
LBBW Asset Management
LBBW Asset Management investment in Series F - CureVac
Baden-Württembergische Versorgungsanstalt für Ärzte
Baden-Württembergische Versorgungsanstalt für Ärzte investment in Series F - CureVac
Landeskreditbank Baden-Württemberg
Landeskreditbank Baden-Württemberg investment in Series F - CureVac
Baillie Gifford
Baillie Gifford investment in Series F - CureVac
Chartwave
Chartwave investment in Series F - CureVac
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-04 | Curevac names Franz-Werner Haas as CEO |
Official Site Inspections
http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
